ibutilide
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
94
Go to page
1
2
3
4
December 02, 2025
Detecting Local Myocardial Spatiotemporal Repolarization Gradients With Clinical Mapping Arrays.
(PubMed, Circ Arrhythm Electrophysiol)
- "Repolarization changes were created using global infusion of ibutilide or pinacidil, or topical application of lidocaine. Although ARI only correlates with uniformly distributed changes in repolarization in the entire myocardium, RepolLoc also provided accurate regional gradient assessment and duration alternans of repolarization. These findings suggest ARI has significant far-field contamination and RepolLoc may provide a better clinical mapping tool for spatiotemporal repolarization gradient mapping."
Journal
July 01, 2025
POLYCYTHEMIA VERA AS A PRECIPITATING FACTOR FOR ATRIAL FIBRILLATION AND NEW-ONSET HEART FAILURE IN A YOUNG PATIENT: A CASE REPORT
(CHEST 2025)
- "The patient was started on intravenous diltiazem, heparin for anticoagulation, diuretics, and ceftriaxone and doxycycline...A TEE was performed to rule out thrombus in the left atrium, and chemical conversion was achieved using IV ibutilide...Following multidisciplinary consultation, the patient was discharged on GDMT and warfarin... PV is a serious hematologic disorder with potential cardiovascular manifestations. Utilizing appropriate diagnostic measures, including history, laboratory findings, and imaging, is crucial in identifying PV as an underlying cause AF and HFrEF. Persistent erythrocytosis and unexplained thrombosis should prompt further evaluation."
Case report • Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Cough • Fatigue • Heart Failure • Hematological Disorders • Infectious Disease • Ischemic stroke • Myocardial Ischemia • Pneumonia • Polycythemia Vera • Pulmonary Disease • Respiratory Diseases • Thrombosis • JAK2
August 22, 2025
Predictive value of ibutilide response for postoperative recurrence following catheter ablation in persistent atrial fibrillation: a retrospective study.
(PubMed, Front Cardiovasc Med)
- "Intraoperative ibutilide responsiveness significantly predicts postoperative AF recurrence in patients undergoing catheter ablation for persistent AF. Assessing ibutilide response may enhance risk stratification and guide personalized treatment strategies."
Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders
July 01, 2025
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
(clinicaltrials.gov)
- P4 | N=27 | Completed | Sponsor: Indiana University | N=16 ➔ 27
Enrollment change • Cardiovascular
April 29, 2025
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
(clinicaltrials.gov)
- P4 | N=73 | Completed | Sponsor: Indiana University | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Apr 2025
Trial completion • Trial completion date
April 18, 2025
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
(clinicaltrials.gov)
- P4 | N=83 | Active, not recruiting | Sponsor: Indiana University | Trial primary completion date: Oct 2025 ➔ Apr 2025
Trial primary completion date
April 11, 2025
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
(clinicaltrials.gov)
- P4 | N=83 | Active, not recruiting | Sponsor: Indiana University | Recruiting ➔ Active, not recruiting
Enrollment closed
January 28, 2025
A SHORT-SHORT CIRCUIT — A CASE OF ATYPICAL AVNRT WITH A LOWER COMMON PATHWAY BLOCK - Hamid Shirwany
(ACC 2025)
- "Afterwards, she required inotropes for cardiogenic shock and developed recurrent SVT resistant to adenosine, amiodarone, and ibutilide.Decision-making: Repeat EPS demonstrated inducible SVT following AH jump with Wenckebach conduction of the AH interval and droped His without a change in the TCL. This case highlights a rare presentation of AVNRT and the importance of recognizing tachycardia-medicated cardiomyopathy."
Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia
February 03, 2025
Effect of the Membrane Environment on Pharmacologic Inhibition of hERG K+ Channel Activity.
(PubMed, JACC Clin Electrophysiol)
- "These results support the idea that the lipid environment of the plasma membrane plays a role in the ability of certain drugs to inhibit hERG channel activity. Differences in membrane cholesterol content may affect the ability of some hERG channel blockers to produce arrhythmogenic behavior."
Journal • Cardiovascular • Ventricular Tachycardia
January 13, 2025
Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study.
(PubMed, Indian J Crit Care Med)
- "Dewan B, Navale S, Shinde S, Chaudhary J. Clinical Efficacy and Safety of Ibutilide in Cardioversion of Atrial Fibrillation or Flutter in Indian Patients: A Multicenter Study. Indian J Crit Care Med 2025;29(1):45-51."
Clinical • Journal • Atrial Fibrillation • Cardiovascular • Pain • Ventricular Tachycardia
January 10, 2025
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
(clinicaltrials.gov)
- P4 | N=83 | Recruiting | Sponsor: Indiana University | Trial completion date: Dec 2024 ➔ Oct 2025 | Trial primary completion date: Dec 2024 ➔ Oct 2025
Trial completion date • Trial primary completion date
November 15, 2024
Chemical Cardioversion of Atrial Arrhythmias with Ibutilide in Children and Adults with Congenital Heart Disease.
(PubMed, Pediatr Cardiol)
- "Presentation in atrial flutter (P = 0.08) and male gender (0.07) showed a trend towards significance. Adverse effects were reported after 8 ibutilide administrations (7.6%, n = 6/8 [75%] female)."
Journal • Cardiovascular • Heart Failure • Pediatrics • Ventricular Tachycardia
October 14, 2024
Mechanisms of Chemical Atrial Defibrillation by Flecainide and Ibutilide.
(PubMed, JACC Clin Electrophysiol)
- "We predict the drug concentrations that promote efficacy of flecainide and ibutilide used in combination for atrial chemical defibrillation. We also predict the potential safety pharmacology impact of this drug combination on ventricular electrophysiology."
Journal • Cardiovascular
October 12, 2024
Drug-induced increase in dispersion of ventricular repolarization in patients with heart failure with preserved ejection fraction.
(PubMed, Int J Cardiol)
- "HFpEF is associated with enhanced response to drug-induced increases in dispersion of repolarization."
Journal • Cardiovascular • Congestive Heart Failure • Heart Failure
August 22, 2024
Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review.
(PubMed, Clin Cardiol)
- "Antiarrhythmics are not uniformly affected by obesity. This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings."
Journal • Review • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Obesity
June 03, 2024
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
(PubMed, Cochrane Database Syst Rev)
- "Despite the low quality of evidence, this systematic review provides important information on electrical and pharmacological strategies to help patients and physicians deal with AF and atrial flutter. In the assessment of the patient comorbidity profile, antiarrhythmic drug onset of action and side effect profile versus the need for a physician with experience in sedation, or anaesthetics support for electrical cardioversion are key aspects when choosing the cardioversion method."
Clinical • Journal • Retrospective data • Review • Anesthesia • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure
May 31, 2024
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
(clinicaltrials.gov)
- P4 | N=16 | Completed | Sponsor: Indiana University | Active, not recruiting ➔ Completed
Trial completion
January 26, 2024
WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION IN AN OTHERWISE HEALTHY YOUNG MALE
(ACC 2024)
- "The patient was instead given 1 mg Ibutilide and 500 mg Procainamide... Prompt recognition of the WPW and AF via ECG is important in the proper treatment of this arrhythmia (usually with class IA, IC, or III antiarrhythmics) to prevent degeneration to VF. We share this case to raise awareness of the detrimental effects of misdiagnosis and mistreatment of a rare yet serious condition."
Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Movement Disorders
January 26, 2024
ENHANCED RESPONSE TO DRUG-INDUCED LENGTHENING OF LATE VENTRICULAR REPOLARIZATION AND INCREASED TRANSMURAL DISPERSION OF REPOLARIZATION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
(ACC 2024)
- "HFpEF is associated with enhanced response to drug-induced increases in TDR and lengthening of late ventricular repolarization."
Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure
March 19, 2024
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
(clinicaltrials.gov)
- P4 | N=16 | Active, not recruiting | Sponsor: Indiana University | Recruiting ➔ Active, not recruiting | N=40 ➔ 16
Enrollment change • Enrollment closed
February 21, 2024
Analysis of the success rate of conversion using ibutilide administration in radiofrequency catheter ablation of persistent atrial fibrillation and its effects on postoperative recurrence.
(PubMed, BMC Cardiovasc Disord)
- "Ibutilide showed to be effective in catheter ablation of AF, the success rate of conversion was correlated with the duration of AF, LA diameter, and NT-proBNP level. Besides, the duration of AF was found as a risk factor for early postoperative recurrence, while ibutilide administration for successful conversion had no influence on predicting postoperative recurrence and had no influence on postoperative maintenance time of sinus rhythm."
Journal • Atrial Fibrillation • Cardiovascular • NPPB
February 16, 2024
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
(clinicaltrials.gov)
- P4 | N=40 | Recruiting | Sponsor: Indiana University | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024
Trial completion date • Trial primary completion date
February 07, 2024
Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis.
(PubMed, Cardiovasc Drugs Ther)
- "Among guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4 h; flecainide is definitely among the most effective for cardioversion within 24 h. Further, randomized controlled trials with predetermined and strictly defined, hemodynamic adverse event outcomes are recommended."
Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Hypotension
January 05, 2024
Treatment of atrial fibrillation.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Atrial Fibrillation • Cardiovascular
January 06, 2024
Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation.
(PubMed, J Surg Res)
- "Within our population, pretreatment with magnesium sulfate followed by ibutilide was associated with increased conversion to NSR. Additionally, we noted that females had a higher conversion rate to NSR compared to males, regardless of whether they were pretreated with magnesium sulfate."
Journal • Atrial Fibrillation • Cardiovascular • Critical care
1 to 25
Of
94
Go to page
1
2
3
4